ChemoMetec (CHEMM.CO) Stock Analysis & AI Equity Report
ChemoMetec (CHEMM.CO) overview
ChemoMetec (CHEMM.CO) stock analysis and AI equity research. For the latest completed financial year, 2024, ChemoMetec reported revenue of DKK 408m and operating profit of DKK 179m; the year-end share price was N/A and market capitalisation was N/A. ChemoMetec is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get ChemoMetec's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-18. Data will be refreshed during report generation.
About ChemoMetec
ChemoMetec develops, manufactures, and sells analytical instruments for cell counting and cell analysis. Its NucleoCounter and XcytoMatic systems are used in biopharmaceutical production, cell and gene therapy, research, and quality control, supported by consumables and software. The company also serves related applications in agriculture and other life science workflows.
Generate the ChemoMetec report
ChemoMetec is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for ChemoMetec and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.